Eledon Pharmaceuticals, Inc.: retained earnings or deficit
Retained earnings or deficit for Eledon Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Eledon Pharmaceuticals, Inc. financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | -401,203,000 | USD | 2026-03-19 | 10-K · 0001193125-26-116164 |
| At date | 2024-12-31 | -355,586,000 | USD | 2026-03-19 | 10-K · 0001193125-26-116164 |
| At date | 2023-12-31 | -319,402,000 | USD | 2025-08-14 | 10-K/A · 0001193125-25-180865 |
| At date | 2023-09-30 | -289,303,000 | USD | 2024-08-19 | 10-K/A · 0000950170-24-098575 |
| At date | 2023-06-30 | -279,397,000 | USD | 2024-08-19 | 10-K/A · 0000950170-24-098575 |
| At date | 2022-12-31 | -202,865,000 | USD | 2024-08-19 | 10-K/A · 0000950170-24-098575 |
| At date | 2021-12-31 | -114,899,000 | USD | 2023-03-30 | 10-K · 0000950170-23-011011 |
| At date | 2020-12-31 | -80,393,000 | USD | 2022-03-24 | 10-K · 0001564590-22-011698 |
| At date | 2019-12-31 | -57,582,000 | USD | 2021-03-31 | 10-K · 0001564590-21-016828 |
| At date | 2018-12-31 | -41,571,000 | USD | 2020-03-17 | 10-K · 0001564590-20-011260 |
| At date | 2017-12-31 | -27,506,000 | USD | 2019-03-28 | 10-K · 0001564590-19-009631 |
| At date | 2016-12-31 | -14,390,000 | USD | 2018-04-02 | 10-K · 0001564590-18-007314 |
| At date | 2015-12-31 | -131,438,000 | USD | 2017-03-03 | 10-K · 0001193125-17-069741 |
| At date | 2014-12-31 | -86,351,000 | USD | 2016-03-10 | 10-K · 0001193125-16-499163 |
| At date | 2013-12-31 | -63,055,000 | USD | 2015-03-26 | 10-K · 0001193125-15-107051 |
Related financial histories
- Eledon Pharmaceuticals, Inc.: total assets
- Eledon Pharmaceuticals, Inc.: total liabilities
- Eledon Pharmaceuticals, Inc.: stockholders equity
- Eledon Pharmaceuticals, Inc.: cash and cash equivalents
- Eledon Pharmaceuticals, Inc.: net income or loss
- Eledon Pharmaceuticals, Inc.: operating cash flow
- Eledon Pharmaceuticals, Inc.: capital expenditure payments
- Eledon Pharmaceuticals, Inc.: financing cash flow
- Eledon Pharmaceuticals, Inc.: investing cash flow
- Eledon Pharmaceuticals, Inc.: basic weighted-average shares
- Eledon Pharmaceuticals, Inc.: diluted weighted-average shares
- Eledon Pharmaceuticals, Inc.: basic earnings per share
- Eledon Pharmaceuticals, Inc.: diluted earnings per share
- Eledon Pharmaceuticals, Inc.: income tax expense or benefit
- Eledon Pharmaceuticals, Inc.: net property, plant and equipment
- Eledon Pharmaceuticals, Inc.: share-based compensation expense
- Eledon Pharmaceuticals, Inc.: operating income or loss
- Eledon Pharmaceuticals, Inc.: current assets
- Eledon Pharmaceuticals, Inc.: current liabilities
- Eledon Pharmaceuticals, Inc.: current accounts payable
- Eledon Pharmaceuticals, Inc.: goodwill carrying amount
- Eledon Pharmaceuticals, Inc.: operating expenses
- Eledon Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Eledon Pharmaceuticals, Inc. / CIK 0001404281
- Captured
- 2026-09-20T08:00:59.875Z
- SEC response SHA-256
4f5cc5be1669d2394918add4693809b2004c1033ce5e8c4625a2a4da5c2f19a1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001404281.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))